CA-HORIZON3.AI
Horizon3.ai, a pioneer in autonomous security solutions, today announced the launch of its Rapid Response service, now part of the NodeZero™ platform. This one-of-a-kind capability marks a significant advancement in autonomous penetration testing solutions by addressing a critical gap in measuring the real-world impact of exploitable vulnerabilities within the software many organizations have come to rely on. Now, organizations can gain a clear understanding of their ‘likelihood of exploitability’ for the most critical vulnerabilities being announced.
As organizations continue to contend with both zero-day and N-day vulnerabilities, the window of time between the public disclosure of a vulnerability and threat actors exploiting them in the wild is steadily shrinking. Knowing this predicament, organizations spend vast amounts of time, money, and resources patching the software they use after hearing of a vendor vulnerability announcement. Yet, how often are organizations expending considerable effort not knowing if a vulnerability is actually exploitable or not? The answer to that is, “quite often.”
So far in 2024, the U.S. National Vulnerability Database (NVD) has tracked 12,296 new vulnerabilities in publicly released software. A common challenge for organizations is determining whether any software they are using that is identified as vulnerable is actually exploitable within their specific environments, a judgment often contingent on how the software is deployed. Since organizations often lack a proven method to assess the ‘exploitability’ of software, they may find themselves updating software that does not require immediate patching. NodeZero addresses this issue with its Rapid Response service, which is specifically tailored to manage many of the most critical vulnerabilities more effectively. The following outlines the workings of the Rapid Response service.
As Horizon3.ai’s attack team conducts original research and uncovers new vulnerabilities, they also keep an eye on public vulnerability disclosures. They assess the exploitability of these vulnerabilities, considering factors such as the ease of exploitation, their severity, and the prevalence of the vulnerable software. Following their assessment, they develop proof of concept (POC) exploits, integrate them into NodeZero as new attack content, and notify customers about these emerging vulnerabilities. With NodeZero, customers can probe their systems using this new attack content to gain immediate insights into their level of exploitability. Furthermore, Horizon3.ai alerts customers if known vulnerable software is present in their production environments and warns them about NodeZero being able to exploit these weaknesses.
The Rapid Response service doesn't just focus on vulnerabilities; it zeroes in on the exploitability of known issues in production environments. As part of this service, organizations receive proactive measures to keep abreast of cyberattacks. The vulnerabilities that flow through this program typically revolve around publicly accessible assets since they are the most likely targets for exploitation.
Recognizing the critical role of response time to emerging exploits in the wild, Horizon3.ai’s Rapid Response service is designed to provide organizations with a proactive defense mechanism to stay ahead of evolving cyberattacks as they’re discovered or trending in the wild. The fundamentals of this type of rapid response effort are concentrated on enabling organizations to preemptively mitigate nascent vulnerabilities before threat actors target them.
"In the swiftly evolving arena of cybersecurity, where threats emerge and proliferate with alarming speed, the essence of a robust defensive posture lies in responding rapidly. We enable organizations to move faster by prioritizing critical vulnerabilities that have the most potential impact on their organization,” says Snehal Antani, CEO and Co-founder of Horizon3.ai. “Our Rapid Response service is engineered to provide a preemptive shield, arming cybersecurity teams with the necessary knowledge, insights, and tools they need to protect their vital infrastructure.”
By leveraging Horizon3.ai's expertise in using ‘offense to inform defense,’ and leaning into NodeZero’s autonomous capabilities, customers can schedule and/or immediately launch NodeZero using a single exploit-check to gain early detection of exploitability from an attacker’s perspective. Once finished, NodeZero prioritizes the most critical and exploitable vulnerabilities that must be patched because they have been deemed completely exploitable by the NodeZero platform.
Horizon3.ai's Rapid Response service is a groundbreaking step forward in the field of cybersecurity, offering organizations an unprecedented level of preparedness against cyber threats. With its cutting-edge technology and proactive strategy, Horizon3.ai is redefining the landscape of cyber defense, providing a critical service that ensures organizations are not only aware of their vulnerabilities but are also equipped to address exploitability with unmatched speed and efficiency. This service, seamlessly integrated into the NodeZero platform, solidifies Horizon3.ai's position as a leader in autonomous security solutions, empowering organizations to fortify their defenses against the unpredictable nature of cyber threats.
Learn more about the Horizon3.ai Rapid Response service.
For more information, send your inquiry to info@horizon3.ai
About Horizon3.ai
The NodeZero™ platform empowers organizations to continuously find, fix, and verify exploitable attack surfaces. It is the flagship product of Horizon3.ai, founded in 2019 by former industry and U.S. National Security veterans. Our mission is to help organizations see their networks through the eyes of the attacker and proactively fix problems that truly matter, improve the effectiveness of their security initiatives, and ensure that they are prepared to respond to real cyberattacks.
Follow Horizon3.ai: LinkedIn and on X, formerly known as Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430324848/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PUMA Becomes Official Partner of the Premier League17.3.2025 12:42:00 CET | Press release
Global sports company PUMA has signed an official agreement with the Premier League, the most-watched football league globally, as part of the company’s strategy to elevate the brand and strengthen its sports performance credibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317329567/en/ Global sports company PUMA has signed an official agreement with the Premier League, the most-watched football league globally, as part of the company’s strategy to elevate the brand and strengthen its sports performance credibility. This landmark collaboration will see PUMA become the Official Ball Supplier of the Premier League, which includes the provision of match balls at all League matches from the start of the 2025/26 season. Through this partnership, PUMA will also support the Premier League across multiple initiatives, from community-based football programs that nurture grassroots talent to high-impact marketing campaigns a
Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa17.3.2025 12:00:00 CET | Press release
- Statistically significant results for primary endpoints in both STOP-HS1 and STOP-HS2 Phase 3 studies for both doses tested - Favorable safety profile, with no safety concerns - Data will support planned regulatory submission for povorcitinib in hidradenitis suppurativa (HS) worldwide - Incyte to hold an analyst and investor call on Monday, March 17, 2025 from 8:00-9:00 a.m. ET Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the t
Adara Ventures Announces First Close of €100M AV4 Fund, Targeting Cybersecurity, AI & Digital Infrastructure17.3.2025 11:03:00 CET | Press release
Adara Ventures, the European venture capital firm specialising in early-stage deep tech investments, today announced the first close of its fourth flagship fund, AV4, targeting €100 million in capital commitments. This new fund reinforces Adara’s commitment to delivering strong returns in strategic sectors, including cybersecurity, applied AI, digital infrastructure, hardware components, digital health, and space. “We are immensely proud to announce the successful first close of AV4,” said Nico Goulet, Founding Partner of Adara Ventures. “Over the past nine months, we have secured in excess of €140 million in commitments across our fourth-generation funds. Alongside AV4, this includes Adara Ventures Energy (AVE), our first Pan-European fund dedicated to energy transition technologies. In one of the most challenging fundraising environments of the past 20 years, our strong DPI record, disciplined investment strategy, and focused fund model make AV4 a compelling opportunity for our limit
Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity17.3.2025 10:22:00 CET | Press release
Neutrophil to Lymphocyte ratio (NLR) is a critical biomarker of health of astronauts during space mission, and that of aging related illnesses, inflammaging, longevity and cancer prognosis. Oral consumption of AFO-202 strain of Aureobasidium pullulans produced Nichi BRITE and N-163 strain produced Neu REFIX together in pre-clinical and clinical studies having safely and beneficially modified NLR, are considered holding potential to help maintain astronauts health during space flight and also to bridge the gap between health span and life span by ‘Me-Byo’ phenomenon as published in Frontiers in Immunology while Neu REFIX standalone yielding enhanced dystrophin, an additional benefit that might help prevent muscle loss during space missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316966059/en/ Astronauts during space missions, deep-sea researchers, high-altitude climbers, and workers exposed to radiation hazards, ar
Cineca to House Italy’s Most Powerful Quantum Computer IQM Radiance 5417.3.2025 10:04:00 CET | Press release
IQM Radiance 54-qubit full-stack superconducting quantum computer will be integrated into Leonardo, one of the world’s fastest supercomputers in Bologna, Italy. Cineca intends to use the system for optimisation of quantum applications, quantum cryptography, quantum communication and artificial intelligence quantum algorithms. IQM Radiance 54-qubit quantum computer is scheduled for delivery and installation in Q4 2025. The system will be the first and most powerful on-prem quantum computer in Cineca. Italian supercomputing centre Cineca today announced an agreement with IQM Quantum Computers, a global leader in superconducting quantum computers, to deliver the most powerful quantum computer in Italy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250317715500/en/ IQM Radiance 54-qubit superconducting quantum computer IQM Radiance quantum computer, powered by IQM’s 54-qubit quantum processing unit (QPU), will be installed in t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom